June 26, 2017 / 12:40 PM / in a month

BRIEF-Zosano Pharma announces outcome of end of phase 2 meetings with FDA

1 Min Read

June 26 (Reuters) - Zosano Pharma Corp

* Zosano Pharma announces outcome of end of phase 2 meetings with FDA

* Zosano Pharma - Received confirmation, a single efficacy study, our recently completed Zotrip trial, is sufficient to support an NDA filing for M207

* Zosano Pharma - FDA concurred that development strategy, which conforms to relevant regulatory guidelines, appears adequate for registration of M207

* Zosano Pharma Corp- Initiating long-term safety study in Q3 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below